S100B content and SOD activity in amniotic fluid of pregnancies with Down syndrome
Cristina Brinckmann Oliveira Netto(Universidade Federal do Rio Grande do Sul), Carlos-Alberto Gonçalves(Universidade Federal do Rio Grande do Sul), Diogo O. Souza(Universidade Federal do Rio Grande do Sul), Roberto Giugliani(Instituto de Biologia Molecular e Celular), Luis Valmor Portela, Maria da Purificação Tavares(Universidade do Porto), Cı́ntia Fochesatto(Universidade Federal do Rio Grande do Sul), Ionara Rodrigues Siqueira(Universidade Federal do Rio Grande)
Cited by 28
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
|Molecular Genetics and Metabolism|2008|216
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study
|Journal of Inherited Metabolic Disease|2014|211